Welcome to LookChem.com Sign In|Join Free
  • or
N-BOC-CYCLOPROPYL-DL-ALANINE is a chemical compound with the chemical formula C12H21NO4 and a molecular weight of 241.30 g/mol. It is a member of the BOC-Amino Acids family, which are intermediate products in the synthesis of complex organic compounds. N-BOC-CYCLOPROPYL-DL-ALANINE is characterized by its white to off-white solid appearance and stability under normal temperature and pressure conditions. It is primarily used in research and development settings, particularly in the pharmaceutical industry for drug synthesis and peptide synthesis processes.

888323-62-4

Post Buying Request

888323-62-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

888323-62-4 Usage

Uses

Used in Pharmaceutical Industry:
N-BOC-CYCLOPROPYL-DL-ALANINE is used as an intermediate product for the synthesis of other complex organic compounds, contributing to the development of new drugs and pharmaceuticals.
Used in Peptide Synthesis:
In the process of peptide synthesis, N-BOC-CYCLOPROPYL-DL-ALANINE is used as an N-BOC protected amino acid. It plays a critical role in the selective protection and de-protection of the amino group, which is essential for the successful synthesis of peptides.

Check Digit Verification of cas no

The CAS Registry Mumber 888323-62-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,8,3,2 and 3 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 888323-62:
(8*8)+(7*8)+(6*8)+(5*3)+(4*2)+(3*3)+(2*6)+(1*2)=214
214 % 10 = 4
So 888323-62-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H19NO4/c1-11(2,3)16-10(15)12-8(9(13)14)6-7-4-5-7/h7-8H,4-6H2,1-3H3,(H,12,15)(H,13,14)

888323-62-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-cyclopropyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid

1.2 Other means of identification

Product number -
Other names boc-l-ala(3-cyclopropyl)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:888323-62-4 SDS

888323-62-4Upstream product

888323-62-4Relevant academic research and scientific papers

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection

Venkatraman, Srikanth,Bogen, Stéphane L.,Arasappan, Ashok,Bennett, Frank,Chen, Kevin,Jao, Edwin,Liu, Yi-Tsung,Lovey, Raymond,Hendrata, Siska,Huang, Yuhua,Pan, Weidong,Parekh, Tejal,Pinto, Patrick,Popov, Veljko,Pike, Russel,Ruan, Sumei,Santhanam, Bama,Vibulbhan, Bancha,Wu, Wanli,Yang, Weiying,Kong, Jianshe,Liang, Xiang,Wong, Jesse,Liu, Rong,Butkiewicz, Nancy,Chase, Robert,Hart, Andrea,Agrawal, Sony,Ingravallo, Paul,Pichardo, John,Kong, Rong,Baroudy, Bahige,Malcolm, Bruce,Guo, Zhuyan,Prongay, Andrew,Madison, Vincent,Broske, Lisa,Cui, Xiaoming,Cheng, Kuo-Chi,Hsieh, Yunsheng,Brisson, Jean-Marc,Prelusky, Danial,Korfmacher, Walter,White, Ronald,Bogdanowich-Knipp, Susan,Pavlovsky, Anastasia,Bradley, Prudence,Saksena, Anil K.,Ganguly, Ashit,Piwinski, John,Girijavallabhan, Viyyoor,Njoroge, F. George

, p. 6074 - 6086 (2007/10/03)

Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 888323-62-4